NeoGenomics Stock
NeoGenomics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Anthony Zook
- Employees
- 2,500
- Market cap
- $2.2 B
- IPO
- 16/03/2004
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a…
NeoGenomics stock: price history
1D
-3.5%
1W
+1.8%
1M
-12.1%
6M
+99.4%
YTD
+41.6%
1Y
+62.0%
2Y
+20.4%
5Y
-61.6%
10Y
+115.1%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~89% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
NeoGenomics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
NeoGenomics, Inc. is a specialized diagnostics company focused on oncology, providing laboratory services across the United States, Europe, and Asia. The business model is divided into two segments: Clinical Services and Pharma Services. Its service portfolio includes highly complex diagnostic procedures such as cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, and molecular DNA/RNA analysis. The customer base comprises a broad spectrum of medical professionals, hospitals, research institutions, and pharmaceutical companies. In addition to clinical diagnostics, the company supports the pharmaceutical industry across all phases from discovery through commercialization of oncology programs.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about NeoGenomics
Analyst assessment of NeoGenomics
PRICE TARGET LOW
US$19.00
CONSENSUS
US$23.50
MEDIAN
US$23.50
PRICE TARGET HIGH
US$28.00
1
STRONG BUY
23
BUY
5
HOLD
1
SELL
0
STRONG SELL
30
TOTAL · Buy
As of: 06/10/2026
NeoGenomics stock metrics
P/E
-8.39
P/B
0.55
EV/EBITDA
191.75
RETURN ON EQUITY
0.3%
NET MARGIN
1.1%
DEBT/EQUITY
0.57
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.0%
FLOAT SHARES
23,393,065
AVG. DAILY VOLUME (30D)
2,209,857
Insider transactions (SEC)
Stone Warren
Stone Warren
Olivo Alicia C
Stone Warren
Stone Warren
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.5%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about NeoGenomics stock
What does NeoGenomics do?
NeoGenomics, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Anthony Zook, the company employs around 2,500 people.
The IPO was on 16/03/2004; the stock trades on NASDAQ under the ticker NEO.
What do analysts say about NeoGenomics stock?
30 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$23.50, ranging from US$19.00 to US$28.00, with a median of US$23.50.
This is an external assessment, not a statement by Market Jury.
When does NeoGenomics report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 89% stronger than usual.
Does NeoGenomics pay a dividend?
Yes. The last dividend was US$0.40 per share, ex-date 17/12/2020, paid on 30/12/2020.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to NeoGenomics?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get NeoGenomics stock analyzed?
Clicking "Analyze stock" lets five strategies assess NeoGenomics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.